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Short- and Long-Term
Effects of Inhaled Iloprost Therapy in
Children With Pulmonary Arterial Hypertension
D. Dunbar Ivy, MD,* Aimee K. Doran, CPNP,* Kelly J. Smith, MD,† George B. Mallory, JR, MD,†
Maurice Beghetti, MD,‡ Robyn J. Barst, MD,§ Daniela Brady, RN,§ Yuk Law, MD,
Donna Parker, RRT,* Lori Claussen, RN,* Steven H. Abman, MD*
Denver, Colorado; Houston, Texas; Geneva, Switzerland; New York, New York; and Seattle, Washington
Objectives This study investigated the short- and long-term outcome of children with pulmonary arterial hypertension (PAH)
treated with inhaled iloprost.
Background Inhaled iloprost has been approved for the treatment of adults with PAH, but little is known about the effects in
children with PAH.
Methods We evaluated the acute effects of inhaled iloprost on hemodynamic status and lung function and the response to
long-term therapy in 22 children (range 4.5 to 17.7 years) with PAH (idiopathic, n 12; congenital heart disease,
n  10). Cardiac catheterization, standard lung function testing before and after iloprost inhalation, 6-min walk test,
World Health Organization functional class, and hemodynamic parameters were monitored.
Results Acute administration of inhaled iloprost lowered mean pulmonary artery pressure equivalent to the response to
inhaled nitric oxide with oxygen. Acute iloprost inhalation reduced forced expiratory volume in 1 s and mid-
volume forced expiratory flow by 5% and 10%, respectively, consistent with acute bronchoconstriction. At 6
months, functional class improved in 35%, decreased in 15%, and remained unchanged in 50% of children.
Sixty-four percent of patients continued receiving long-term iloprost therapy, 36% stopped iloprost, due to lower
airway reactivity, clinical deterioration, or death. In 9 patients on chronic intravenous prostanoids, 8 transitioned
from intravenous prostanoids to inhaled iloprost, which continued during follow-up.
Conclusions Inhaled iloprost caused sustained functional improvement in some children with PAH, although inhaled iloprost occasionally
induced bronchoconstriction. Most patients tolerated the transition from intravenous to inhaled prostanoid therapy. Clinical
deterioration, side effects, and poor compliance, owing to the frequency of treatments, could limit chronic treatment in
children. (J Am Coll Cardiol 2008;51:161–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.031s
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Pulmonary arterial hypertension (PAH) is characterized by
levation of pulmonary artery pressure (PAP) and pulmo-
ary vascular resistance (PVR), which can lead to progres-
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007, accepted September 7, 2007.ive right heart failure and death (1–4). Pulmonary arterial
ypertension occurs in diverse clinical settings, such as in
ssociation with congenital heart disease, chronic lung
isease, connective tissue disease, liver disease, and anorexi-
en use, or could be idiopathic or familial (5,6). Before the
evelopment of intravenous (IV) prostacyclin as a chronic
herapy for PAH, the National Health Registry estimated
hat the median survival after diagnosis was 2.8 years for
dults and 0.8 years for children with idiopathic PAH (7).
ver the past decade, significant advances in the pharma-
ologic treatment of PAH have improved survival; however,
here remains no cure (8–12). On the basis of advances in
ascular biology and known pathogenic mechanisms under-
ying PAH, 3 general classes of therapeutic agents have been
eveloped and are currently available for the treatment of
AH. These include: prostacyclin analogues (epoprostenol,reprostinil, and iloprost), endothelin receptor antagonists
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phosphodiesterase inhibitors (sil-
denafil) (3,13–24).
Until recently, chronic treat-
ment with prostacyclin analogues
has required IV or subcutaneous
administration, with each ap-
proach limited by such problems
as line infections, thrombosis, or
site pain. Previous studies of in-
haled iloprost have been per-
formed in adult patients. In 1
large multicenter, randomized,
placebo-controlled trial of ilo-
prost therapy for 3 months, a
larger percentage of patients on
iloprost demonstrated the com-
bined end point of at least a
10% improvement in the 6-min
walk (6MW) distance and im-
provement in World Health Or-
anization (WHO) functional class, with no deterioration
r death versus patients on placebo (16).
Most recently, inhaled iloprost has been studied in
atients who remain symptomatic (WHO functional class
II or IV) on bosentan therapy (25). In this multicenter,
andomized, controlled trial, 67 patients with PAH were
andomized to receive inhaled iloprost or placebo. There
ere significant improvements in 6MW distance, WHO
unctional class, time to clinical worsening, and post-
nhalation mean PAP and PVR. Combination therapy
ppeared safe and well tolerated. Although extensively
tudied in adults with PAH, little is known about efficacy of
loprost in children, especially with regard to long-term
herapy (16,17,25–30). Therefore, to determine the poten-
ial role for inhaled iloprost therapy in children with PAH,
e retrospectively evaluated the acute and chronic effects of
nhaled iloprost in children with PAH.
ethods
tudy population. To evaluate the safety, tolerability, and
linical effects of inhaled iloprost in children with PAH, we
eviewed data from all children with PAH who were treated
ith inhaled iloprost before August 2006 at 5 pediatric
ulmonary hypertension clinics. Each institution received
nstitutional review board approval or exempt status.
atient selection and approach to dosage and treatment.
ndications for initiation of iloprost therapy included newly
iagnosed PAH (n  3), perceived inadequate response to
rior therapy or refusal to initiate IV prostanoid therapy (n
10), and transition from IV or subcutaneous prostanoids
n 9; 3 of 9 transitioned for recurrent central line infections;
of 9 for site pain; 5 of 9 per patient request for noninvasive
herapy). After insurance approval, iloprost (Ventavis, Actelion
Abbreviations
and Acronyms
6MW  6-min walk
FEV1  forced expiratory
volume in 1 s
FEF25–75  mid-volume
forced expiratory flow
FVC  forced vital capacity
IV  intravenous
NO  nitric oxide
PAH  pulmonary arterial
hypertension
PAP  pulmonary arterial
pressure
PVR  pulmonary vascular
resistance
TLC  total lung capacity
WHO  World Health
Organizationnc., South San Francisco, California) was administered by fnhalation with the Prodose AAD (Profile Therapeutics
LC, West Sussex, United Kingdom) or Ineb Adaptive
erosol Delivery System (Respironics Inc., Murrysville,
ennsylvania) delivery devices. The initial dose of inhaled
loprost was 2.5 g (with the exception of 1 patient initiated
t 0.625 g). Iloprost therapy was initiated during hospital
tay or in the clinic setting, depending upon patient stabil-
ty. Patients with side effects or difficulty tolerating the
uration of each treatment were maintained on the initial
ose for several weeks or months. Those with minimal to no
ide effects were increased to 5 g and, if tolerated,
aintained at that dose for chronic therapy. Some patients
ere increased to a dose of 7.5 g/dose. The dose of iloprost
ould be reduced if adverse effects were noted, with plans to
ncrease the dose again as tolerated. The frequency of dosing
as initiated at 5 to 9 inhalations daily but titrated individ-
ally according to severity of illness, tolerability, and patient
ompliance.
Patients transitioning from IV epoprostenol or IV tre-
rostinil to iloprost were hospitalized for 24 to 96 h in a
ediatric intensive care unit for monitoring at the time of
nitiation of inhaled iloprost therapy. Transition methods
aried, but in general, patients were initiated at 2.5 g
loprost while remaining on their baseline dose of IV
rostanoid therapy. Two to 3 h later, iloprost 5 g was
dministered and repeated every 2.5 to 3 h while awake,
uring which time the IV prostanoid therapy dose was
ecreased. One patient increased to 7.5 g/dose every 3 h
fter 24 h. The rate of IV prostanoid weaning varied from
0% reductions every 6 h to an initial 50% reduction
ollowed by 10% serial dose reductions after 24 h. One
atient transitioned from subcutaneous treprostinil over a
-day period with frequent clinic visits. Reduction of
rostanoid dose occurred primarily during the day to ensure
ccurate assessment of symptoms and side effects related to
evere PAH, including concerns for the risk of acute
ulmonary hypertensive crisis.
cute assessments. Before the initiation of iloprost ther-
py, assessments included: cardiac catheterization (n  22),
ulmonary function tests (n  13), 6MW distance (n 
3), and assessment of WHO functional class (n  22) on
he basis of physician judgment and age of the patient.
ardiac catheterization at baseline included acute vasoreac-
ivity testing to assess the hemodynamic response of inhaled
loprost (5 g) and inhaled nitric oxide (NO) (40 ppm) with
xygen (n  8). Baseline pulmonary function measure-
ents, spirometry and lung volumes, were performed with
tandard methods before and after inhalation of iloprost to
tudy acute changes in lung function. Study parameters
easured included forced expiratory volume in 1 s (FEV1),
orced vital capacity (FVC), FEV1/FVC ratio, mid-volume
orced expiratory flow (FEF25–75), total lung capacity
TLC), residual volume (RV), and RV/TLC ratio. These
easurements were performed with a SensorMedics
max22 (SensorMedics Corporation, Yorba Linda, Cali-ornia) system.
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January 15, 2008:161–9 Iloprost in Pediatric Pulmonary HypertensionThe 6MW test was performed in children 8 years of age
nd older. Patients were instructed to walk at their own pace
ut to walk as far as possible in 6 min. Patients were allowed
o stop during the walk if needed for symptoms and resume
gain when able. The test was performed in a covered
orridor and the patient did not receive encouragement. At
ompletion of the 6 min, the total distance covered was
easured and recorded. The functional class was assigned
n the basis of standard WHO definitions.
The acute response to inhaled iloprost and comparisons
ith the effects of inhaled NO were studied by cardiac
atheterization in 8 patients. Candidates for studies of
nhaled iloprost were patients who were undergoing cardiac
atheterization for clinical care, independent of this study
rotocol, and consent was obtained before study. Patients
ere newly diagnosed (n  3) or continued on chronic
herapy before catheterization. At cardiac catheterization,
atients were sedated with fentanyl and midazolam. Arterial
nd venous access was obtained by the femoral approach via
tandard techniques. Cardiac output was measured in trip-
icate by thermodilution technique or by the Fick equation
ith measured oxygen consumption. Study measurements
ncluded mean PAP, pulmonary capillary wedge pressure,
ean aortic/systemic arterial pressure, right atrial pressure,
ardiac index, pulmonary vascular resistance (PVR) index,
ystemic vascular resistance (SVR) index, and PVR/SVR
atio. Pulmonary and systemic vascular resistances were
ndexed for body surface area and expressed as PVR index
nd SVR index, respectively, in Wood units (U  m2).
After obtaining baseline hemodynamic measurements,
he acute response to inhaled NO was measured during
dministration of NO at 40 ppm by facemask. All patients
ere allowed to equilibrate in each given condition for at
east 10 min before the hemodynamic responses were
easured. After NO administration, patients were returned
o baseline status, and then iloprost was administered with
he Prodose AAD or Ineb delivery devices at a dose of 5 g.
o achieve delivery with sedated patients in a supine
osition, a PARI mask set (PARI Respiratory Inc., Mid-
othian, Virginia) with Y-piece expiratory valve was con-
ected to corrugate tubing and attached to the mouthpiece
f the delivery device. Sealing of the mask on the patient’s
ace allowed for appropriate triggering of the device.
hronic therapy. Outpatient dose titration of iloprost was
ased upon a perceived balance between prostanoid side
ffects and pulmonary hypertension symptoms. Biweekly or
eekly phone contact with the patient continued until their
rst follow-up visit. Follow-up visits occurred from 2 weeks
o 6 months after initiation of iloprost, depending on
linical course. Evaluations at the follow-up visits included
hysical examination, echocardiogram, 6MW test, and
HO functional class. Repeat cardiac catheterizations were
reformed in some patients (n  12; 3 clinical worsening, 9
cheduled follow-up) on the basis of the investigator’s
linical judgment. All adverse events were assessed during
hone and clinic appointments and recorded. aata analysis. Data analyzed included: hemodynamic pa-
ameters during acute vasoreactivity testing with inhaled
O followed by inhaled iloprost, exercise capacity as mea-
ured by the 6MW test, functional assessment according to
he WHO classification, pulmonary function tests before
nd after iloprost inhalation measuring forced expiratory
olume of air in 1 s (FEV1.0), and mid-volume forced
xpiratory flow rate (FEF25%–75%). Data are expressed as
edian and range for some of the descriptions of the study
opulation or as mean  SD. Analysis for statistically
ignificant differences was performed with paired t test or
ith repeated measures analysis of variance with Tukey-
ramer multiple comparisons post hoc test.
esults
atient population. We studied the effects of inhaled
loprost in 22 pediatric PAH patients (12 male, 10 female),
ith a median age of 11.5 years (range 4.5 to 17.7 years) and
edian body weight of 35.6 kg (range 15 to 73 kg) (Table 1).
ulmonary arterial hypertension was idiopathic or familial in
2 patients and associated with congenital heart disease in
0 patients, which included the following diagnoses: unre-
aired heart disease in 1 (atrial septal defect) and surgically
epaired disease in 9 patients (atrial septal defect; ven-
ricular septal defect; ventricular septal defect with patent
uctus arteriosus; ventricular septal defect with coarcta-
ion of the aorta; D-transposition of the great arteries
epaired by the arterial switch procedure; patent ductus
rteriosus with left pulmonary artery stenosis and congenital
iaphragmatic hernia; patent ductus arteriosus; partial atrio-
entricular canal; and double-outlet right ventricle with
atent ductus arteriosus and coarctation of the aorta).
Because a recent publication reported that anatomical
irway obstruction might be present in as many as 25% of
hildren with PAH (31), previous chest tomographies were
eviewed, if available. Of 17 patients, 1 showed evidence of
pper airway obstruction caused by tonsillar hypertrophy
tonsillectomy performed) and another showed compression
f left main bronchus by the aorta. Fifty-three percent
howed pulmonary artery enlargement and 18% had ground
lass appearance.
At the time of iloprost initiation, 19 patients were treated
ith at least 1 other PAH therapy (Table 1). Concomitant
herapies included IV treprostinil (n  5), IV epoprostenol
n 3), subcutaneous treprostinil (n 1), sildenafil (n 16),
osentan (n  11), and calcium channel blockers (n  3)
Table 1). Seven patients had concomitant PAH therapies
dded for inadequate response to therapy (Patients #2, #4,
9, #12, #17, #21, and #22) at a median time of 2.4 months
fter the initiation of iloprost. Bosentan doses were consis-
ent with those recommended in the pediatric pharmacoki-
etic trial (32). The median sildenafil dose was 40 mg three
imes a day (3.5 mg/kg/dose) and did not change signifi-
antly during the study period. In 2 patients (Patients #3
nd #21), concomitant PAH therapy at initiation was
Baseline Characteristics
Table 1 Baseline Characteristics
Patient # Gender Diagnosis
Weight
(kg)
Age
(yrs)
Ventavis
Duration
(yrs)
PAPm
(mm Hg)
PCWPm
(mm Hg)
AOPm
(mm Hg)
RAPm
(mm Hg)
CI
(l/min/m2)
PVRI
(U  m2) PVR/SVR
WHO
Class
6MW
(m)
PH
Medications
at Transition
1 F IPAH 15 5 1.1 47 11 76 8 3.3 10.9 0.5 3 NA BOS, SIL
2 M IPAH 16 6 7.9 73 8 67 5 5.6 25.0 2.2 4 120 CCB
3 F CHD/repaired 22 7 0.9 37 8 50 4 4.6 6.0 0.6 3 NA BOS, SIL
4 M IPAH 32 8 5.2 66 6 57 6 2.6 23.0 1.2 4 100
5 M CHD/repaired 28 9 1.1 76 5 81 6 3.2 18.7 0.9 3 446 BOS, SIL
6 M IPAH 33 10 1.0 62 8 66 4 2.4 12.9 0.9 2 492 BOS, SIL
7 M IPAH 38 10 1.1 42 11 84 2 3.0 9.0 0.4 2 480 IV EPO, CCB,
BOS, SIL
8 M FPAH 27 11 0.9 28 10 78 8 4.7 3.9 0.3 2 462 IV EPO, BOS
9 M IPAH 32 11 1.7 84 12 69 9 2.9 25.1 1.4 3 423 BOS
10 M IPAH 33 11 0.1 70 6 67 6 2.9 22.4 1.1 3 582 IV TRE, SIL
11 F CHD/repaired 41 11 0.1 70 7 72 6 1.6 15.8 0.9 2 482 BOS, SIL
12 M IPAH 56 12 5.6 71 13 69 8 4.8 37.0 2.9 3 475
13 M CHD/repaired 33 13 0.7 65 9 70 4 3.5 16.9 0.9 2 583 IV TRE, BOS,
SIL
14 F CHD 28 13 1.1 83 12 68 7 3.4 26.1 1.5 3 435 IV TRE, SIL
15 F CHD/Repaired 73 13 0.2 82 10 87 13 3.3 21.8 1.0 3 360 SIL, CCB
16 M CHD/repaired 58 14 1.1 60 6 67 6 3.7 12.7 0.8 3 494 SQ TRE, SIL
17 F CHD/repaired 46 14 1.0 60 7 84 7 2.8 35.3 1.3 2 542 IV EPO, SIL
18 F CHD/repaired 44 16 0.5 77 12 68 12 1.9 34.0 1.2 3 434 BOS, SIL
19 F IPAH 44 16 0.1 55 8 70 6 2.8 14.7 0.7 3 534 BOS, SIL
20 F CHD/repaired 46 17 0.9 52 8 62 5 4.7 9.3 0.8 3 300 IV TRE, SIL
21 F FPAH 64 17 0.9 82 8 75 15 1.4 54.9 1.2 4 278
22 M IPAH 65 18 0.6 70 3 64 3 2.1 22.7 0.8 2 469 IV TRE, SIL
Mean  SD 40  16 12  4 1.5  2.0 64  15 9  3 70  9 7  3 3.2  1.1 20.8  11.9 1.1  0.6 2.8  0.7 425  133
6MW 6-min walk (test); AOPmmean arterial pressure; BOS bosentan; CCB calcium channel blocker; CHD congenital heart disease; CI cardiac index; EPO epoprostenol; FPAH familial pulmonary arterial hypertension; IPAH idiopathic pulmonary arterial
hypertension; IV intravenous; PAPmmean pulmonary artery pressure; PCWPmmean pulmonary capillary wedge pressure; PH pulmonary hypertension; PVR pulmonary vascular resistance; PVRI pulmonary vascular resistance index; RAPmmean right atrial
pressure; SIL  sildenafil; SQ  subcutaneous; SVR  systemic vascular resistance; TRE  treprostinil; WHO  World Health Organization.
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January 15, 2008:161–9 Iloprost in Pediatric Pulmonary Hypertensioniscontinued after iloprost initiation at a median time of 3
onths.
cute hemodynamic and pulmonary effects of inhaled
loprost. Cardiac catheterization was performed in all pa-
ients before the initiation of iloprost (n  22) (Table 1).
aseline hemodynamic status demonstrated significant
AH (i.e., mean PAP 64  15 mm Hg [mean  SD;
edian 68 mm Hg, range 28 to 84 mm Hg]) and a
ulmonary to systemic vascular resistance index ratio of
.1  0.6. Of these 22 patients, 8 (Patients #2, #5, #6, #7,
11, #13, #19, and #21) had acute pulmonary vasoreactivity
esting with inhaled NO and iloprost (Table 2). Reduction
n the mean PAP by inhaled NO and iloprost were
imilar (Fig. 1). Inhaled NO (40 ppm) reduced mean
AP from 66  13 mm Hg at baseline to 58  18 mm
g (p  0.05 vs. baseline), representing a reduction of
2% for the entire study group. The reduction in mean
AP after acute inhalation of iloprost (57  19 mm Hg;
 0.05 vs. baseline) was similar to the level achieved
ith inhaled NO therapy. Neither inhaled NO nor
nhaled iloprost significantly lowered PVR. The PVR/
VR ratio fell from 1.0  0.5 at baseline to 0.8  0.4
p  0.05) after iloprost inhalation. There were no
ignificant changes from baseline values for cardiac index,
ulmonary capillary wedge pressure, or right atrial pres-
ure, during the acute treatment with either NO or
loprost. Two patients (Patients #6 and #7) had a
ecrease in mean PAP of at least 20% in response to
nhaled NO and inhaled iloprost.
The acute effects of inhaled iloprost were also assessed by
ulmonary function tests before the initiation of chronic
loprost therapy in 13 patients. Baseline FEV1 (expressed as
predicted) was 84  16% (range 56% to 119%), which
ecreased to 79  15% after a single inhalation of iloprost
p 0.02) (Fig. 2). At baseline, mean FEF25–75 was 82% of
redicted (range 32% to 119%). After iloprost inhalation,
ean FEF25–75 decreased to 72  29% (p  0.03) (Fig. 3).
n 5 of 13 (38%) patients, FEF25–75 decreased by more than
5% (range 53% to 17%). Two of these patients did not
eceive chronic iloprost therapy, owing to symptomatic
ower airway obstruction.
cute Hemodynamic Effects of Inhaled Iloprost
Table 2 Acute Hemodynamic Effects of Inhaled Iloprost
Baseline
(n  8)
iNO With 100% O2
(n  8)
Inhaled Iloprost
(n  8)
RAPm (mm Hg) 6 4 6 3 6 3
SAPm (mm Hg) 73 6 73 6 75 7
PCWPm (mm Hg) 8 2 8 2 8 3
CI (l/min/m2) 2.9 1.3 2.8 1.3 3.1 1.4
PVRI (U  m2) 21 14 18 17 17 15
PVRI/SVRI 1.0 0.5 0.9 0.7 0.8 0.4*
alues mean  SD. Analysis with repeated measures analysis of variance with Tukey-Kramer
ultiple comparisons post hoc test. *p  0.05 vs. baseline.
iNO  inhaled nitric oxide; CI  cardiac index; PCWPm  mean pulmonary capillary wedge
ressure; PVRI  pulmonary vascular resistance index; RAPm  mean right atrial pressure;
APm  mean systemic arterial pressure; SVRI  systemic vascular resistance index.hysiologic effects of chronic iloprost therapy. The me-
ian duration of iloprost therapy was 0.9 years (range 0.1 to
.9 years). At initiation (n 22) the median dose of iloprost
as 5 g (range 0.63 to 10 g), with a frequency of 6 times
aily (range 4 to 9) and total daily dose of 30 g/day (range
.75 to 50 g/day) (Table 3). At 6 months, 18 patients
ontinued on iloprost therapy; the median dose was 5 g
range 2.5 to 10 g), with a median frequency of 6 times
aily and a total daily dose of 30 g/day (range 13.75 to 50
g/day). Twelve patients remained on therapy for 12
onths or longer. At one year, the median dose was 5 g
range 5 to 10 g), with a median frequency of 6 times daily
nd total daily dose of 30 g/day (range 25 to 50 g/day).
Follow-up cardiac catheterizations were performed in 12
atients (Patients #1, #2, #3, #4, #5, #6, #8, #9, #12, #16,
18, and #21) to assess the response to long-term iloprost
herapy at trough before iloprost inhalation at a mean
ollow-up period of 10 months (range 3 to 24 months)
Table 4). In comparison with baseline hemodynamic sta-
Figure 1 Acute Inhalation of Iloprost Lowered Mean PAP
Equivalent to the Response to 40 ppm Inhaled NO
Inhaled nitric oxide (NO) (40 ppm) reduced mean pulmonary artery pressure
(PAP) from 66  13 mm Hg at baseline to 58  18 mm Hg (p  0.05 vs.
baseline); n  8. The reduction in mean PAP after acute inhalation of iloprost
was similar to the level achieved with inhaled NO therapy (57  19 mm Hg;
p  0.05 vs. baseline).
Figure 2 The Acute Effects of Inhaled Iloprost Were Assessed
by Pulmonary Function Tests in 13 Patients
Baseline forced expiratory volume in 1 s (FEV1) (expressed as % predicted) was
84% (range 56% to 119%) and decreased after a single inhalation of iloprost to
79% (range 18% to 3%; p  0.02).
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Iloprost in Pediatric Pulmonary Hypertension January 15, 2008:161–9us, there were no differences in mean PAP, cardiac index,
VR index, or PVR/SVR ratio. In a subgroup of patients (n
7) receiving inhaled NO during the initial and follow-up
ardiac catheterizations, the acute response to inhaled NO
id not change, despite chronic iloprost therapy.
The 6MW tests were obtained for 13 of 22 patients at
aseline and after 6 months (Fig. 4). Overall, there was no
hange in 6MW distance from baseline (n  13; 397 m) to
months (n  13; 428 m); however, 6MW distance did
ncrease by 10% in 5, was unchanged in 7, and decreased
y 10% in 1 child. By comparison, the mean 6MW
istance was 355 m with an average improvement of 30 m
n 12 weeks in the adult trial of iloprost as an add on therapy
o bosentan (25).
The median WHO functional class of the 22 patients at
aseline was class III. Among the 20 patients that remained
n therapy at 6 months, WHO class improved in 7 patients,
emained unchanged in 10 patients, and worsened in 3
atients (Fig. 5). Of these 20 patients, 13 were receiving
loprost therapy for 12 months or longer. During the second
-month period, the functional class improved in 2 patients,
eclined in 3 patients, and remained unchanged in 8
atients.
afety and tolerability. The most common side effects
eported were headache (36%), cough (23%), and dizziness
14%), which generally improved within several days of
Figure 3 Acute Effects of Inhaled Iloprost Were Assessed
by Pulmonary Function Tests in 13 Patients
At baseline, mean mid-volume forced expiratory flow (FEF25%–75%) was 82% of
predicted (range 32% to 119%). After iloprost inhalation, mean FEF25%–75%
decreased to 72% of predicted (p  0.03). In 5 of 14 (38%) patients, FEF25%–75%
decreased by more than 15% (range 53% to 17%).
loprost Dosing
Table 3 Iloprost Dosing
Initiation
(n  22)
6 Months
(n  18)
12 Months
(n  12)
Dose (g) 5 2 5 1.9 5 2
Range (0.63–10) (2.5–10) (5–10)
2.5/5.0/ 5.0 8/12/2 2/13/3 0/10/2
Frequency (/day) 6 1 6 0.7 6 0.7
Range (4–9) (4–7) (5–7)
Total daily dose (g) 30 13 30 10 30 8Range (3.75–50) (13.75–50) (25–50)nitiation. Two patients experienced syncope during the
tudy period, which could have been related to noncompli-
nce with recommended frequency. Although 5 patients
23%) were initiated at 7 to 9 treatments daily, within 9
onths, all patients remaining on iloprost reported 5 to 6
reatments daily, owing to the time required for treatments.
Of the 22 patients, 6 (27%) had marked deterioration
uring the study period (Fig. 6). Two deaths occurred, and
patients were transitioned to IV prostanoid therapy. Two
atients (Patients #15 and #22) died 2 and 6 months,
espectively, after initiation of inhaled therapy and refused
V prostanoid therapy. Four patients were transitioned to
V prostanoid therapy from inhaled iloprost for clinical
eterioration (Patients #2, #3, #5, and #21).
In 9 patients on chronic IV prostanoids, 8 tolerated the
ransition from IV prostanoids to inhaled iloprost therapy
Fig. 6). One patient had a moderate fall in systemic arterial
xygen saturations through an unrepaired atrial septal defect
ut elected to remain on inhaled iloprost, owing to recurrent
nd severe central venous line infections. Among the tran-
ition patients, 1 death occurred 7 months after the transi-
ion (owing to worsening PAH).
Figure 4 6MW Tests Were Obtained for 13
of 22 Patients at Baseline and After 6 Months
Overall, there was no change in 6-min walk distance (6MWD) from baseline
(397 m) to 6 months (428 m); however, 6MWD did increase by 10% in 5,
was unchanged in 7, and decreased by 10% in 1 child.
hronic Hemodynamic Effects of Inhaled Iloprost
Table 4 Chronic Hemodynamic Effects of Inhaled Iloprost
Baseline
(n  12)
Median Follow-Up 10 Months
(Range 3–24 Months)
(n  12)
PAPm (mm Hg) 64 18 64 13
RAPm (mm Hg) 8 3 6 2
SAPm (mm Hg) 69 9 68 7
PCWP (mm Hg) 9 3 7 2
CI (l/min/m2) 3.4 1.3 3.6 1.4
PVRI (U  m2) 22 15 19 7
PVR/SVR 1.2 0.7 1.1 0.4
alues mean  SD. Analysis with repeated measures analysis of variance with Tukey-Kramer
ultiple comparisons post hoc test. p  0.05 vs. baseline.
PAPm  mean pulmonary artery pressure; other abbreviations as in Table 2.
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January 15, 2008:161–9 Iloprost in Pediatric Pulmonary HypertensionTwo patients without a prior history of lung disease
iscontinued initial therapy, owing to persistent cough and
yspnea (Fig. 6). In Patient #11, inhaled iloprost was
iscontinued after a single dose of 2.5 g. In this patient,
redicted FEV1 decreased by 18% and FEF25–75 decreased
y 53%. A repeat trial of 2.5 g during cardiac catheteriza-
ion produced audible wheezing, respiratory distress, and a
ecrease in room air oxygen saturation from 95% to 88%. In
atient #19, iloprost was discontinued after 48 h (dose, 2.5
g 6 times daily), owing to complaints of tingling in the
hest and shortness of breath, accompanied by a decrease in
oom air oxygen saturation from 100% to 89% after iloprost
nhalation. Pre-treatment spirometry showed a decrease in
redicted FEV1 of 12% and a decrease in FEF25–75 of 20%
fter inhalation of iloprost.
Two patients became symptomatic with signs of lower
irways obstruction several months after initiation of ilo-
rost. One patient (Patient #20) had congenital scoliosis
nd a history of wheezing. Both patients were initiated on
hronic inhaled corticosteroids and beta-agonist agents and
ubsequently tolerated chronic iloprost therapy.
Figure 5 Of 22 Patients, 20
Remained on Therapy at 6 Months
World Health Organization (WHO) class improved in 7 patients,
remained unchanged in 10 patients, and worsened in 3 patients. BL  baseline.
Figure 6 Of the 22 Patients Treated With Iloprost, 9 Were Tran
In 13 children, iloprost was used as add-on or de novo therapy. Of the 13 patients
transition to intravenous (IV) prostanoids. Two patients discontinued iloprost, owiniscussion
lthough inhaled iloprost therapy is currently approved for
he treatment of PAH in adults, little is known about the
ffects of inhaled iloprost in children. In this open-labeled
bservational study, we examined the acute and chronic
ffects of inhaled iloprost in 22 children with idiopathic or
amilial PAH or PAH associated with congenital heart
isease. We report that: 1) the acute pulmonary vasodilator
esponse to inhaled iloprost is equivalent to the effects of
nhaled NO; 2) acute inhalation of iloprost induces acute
ntrathoracic airways obstruction in some children, as dem-
nstrated by cough and reductions in FEV1.0 and FEF25–75
y pulmonary function tests; 3) the addition of inhaled
loprost therapy reduces the need for IV prostanoid therapy
n some patients; and 4) some patients may clinically
eteriorate during chronic inhaled iloprost therapy requiring
escue therapy with IV prostanoids.
These data must be interpreted with caution with regard
o recommendations for treatment. Further studies are
equired before such recommendations might be made.
owever, the physicians treating these patients seemed to
se iloprost in several settings. In general, iloprost was not
sed as de novo or monotherapy, unless other therapies were
ot available. Most children had a perceived “inadequate
esponse” to other PAH agents and required additional
herapy. Inhaled iloprost was chosen over IV therapy in
hose with a perceived inadequate response to oral
herapy, mostly owing to patient preference. Because
ome children deteriorated while receiving inhaled ilo-
rost therapy, prognostic predictors of the response to
loprost are needed. Children with severe disease warrant
lose monitoring; 5 of 6 children who died or required IV
rostanoid rescue were WHO class III to IV with a 6MW
istance 450 m.
It is interesting that most of the children who were
ransitioned from IV therapy to inhaled iloprost tolerated
he transition without marked clinical worsening. It is likely
ned From IV Prostanoids With 8 Tolerating the Transition
main on therapy and 4 required
irways reactivity, and 1 patient died. SQ  subcutaneous.sitio
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Iloprost in Pediatric Pulmonary Hypertension January 15, 2008:161–9hat these children had been treated with IV prostanoids for
ufficient time to obtain clinical benefit, as has been previ-
usly shown (33). Iloprost in addition to other background
herapy, such as bosentan or sildenafil, was able to maintain
his effect, but long-term follow-up is required. Owing
o the presence of frequent central venous line infections in
ome patients, removal of the central venous line and
pparent maintenance of efficacy on an inhaled therapy was
eneficial. The transition from IV epoprostenol or trepros-
inil to inhaled iloprost in most patients was tolerated
ithout clinical worsening. One patient had decreased
ystemic arterial oxygen saturations, and in another child,
linical deterioration and death occurred after transition to
loprost. Thus, close clinical monitoring is critical, as is
atient education regarding the potential for deterioration
nd need for re-initiation of parental prostanoid therapy.
This study did not evaluate a dose-response effect of
loprost. In most of our patients, the final dose of iloprost
as similar to that used in adult patients, and side effects
ere similar. However, some younger children only toler-
ted a dose of 2.5 g/treatment. Furthermore, some chil-
ren decreased the number of treatments per day on their
wn. This might have been tolerated, owing to the presence
f background therapy.
In 2 children, iloprost was discontinued almost immedi-
tely, owing to apparent airway reactivity; neither patient
ad a history of lung disease. In these 2 patients, decreases
n percent predicted FEV1 by 12% and in percent pre-
icted FEF25–75 by 20% upon inhalation of iloprost were
ocumented. Two additional patients also had late onset of
irway reactivity with initiation of iloprost, which improved
ith albuterol. However, because delivery of inhaled med-
cation is dependent on pulmonary function, iloprost-
nduced lower airway obstruction could potentially affect
rug delivery. It is likely that iloprost intolerance due to
irway reactivity could be predicted via spirometric measure-
ents obtained before and after inhalation at the onset of
herapy; this requires further study. It might also be possible
o ameliorate this effect with daily fluticasone/salmeterol
nhalation therapy, as suggested by the clinical course of
atients #17 and #20; this also requires further study.
ulmonary function testing before and after inhaled iloprost
hould be routinely considered in pediatric patients with
AH before initiation of chronic iloprost therapy and at an
nterval several months after initiation or with any airway
ymptoms.
The mechanism for airway reactivity after inhalation of
loprost is unclear from our study. Although some individ-
als were symptomatic after iloprost and experienced re-
uced lung function, others were not. Intrathoracic airways
bstruction with airway reactivity has been reported recently
n pediatric patients with PAH (34). The drop in airflow
fter inhalation of iloprost could be caused by constriction of
ronchial smooth muscle due to the chemical impact of
loprost or its carrier. However, an increase in pulmonary
rterial blood flow in the medium-to-small pulmonaryrteries could have a compressive effect on the neighboring
mall bronchi and bronchioles. Furthermore, although air-
ay obstruction with response to bronchodilator is a hall-
ark of asthma, there is reason to believe that these
ndividuals are not typical asthma patients. It is uncommon
or them to have histories of frank wheezing or episodes of
ignificant dyspnea. Of the patients demonstrating airway
eactivity, none showed evidence of anatomical airway
bstruction on chest computed tomography. Our data
uggest a careful, individually tailored approach with lung
unction testing for children with PAH receiving iloprost
reatment.
Previous investigators have suggested that evaluation of
cute pulmonary vasoreactivity with inhaled NO and with
nhaled iloprost in children with PAH and congenital heart
isease could reflect the degree of vasodilatory capacity of
he pulmonary vessels and thus the likelihood of response to
ong-term therapy (17,35–38). Evaluation of vasoreactivity
t the initiation of iloprost therapy might prove to be a
seful indicator of the likelihood of clinical response;
owever, a large series of patients will be needed to evaluate
his.
onclusions
his series describes the safety and efficacy of inhaled
loprost in pediatric patients with PAH. Most children
olerated combination therapy with either an endothelin
eceptor antagonist and/or phosphodiesterase inhibitor. Im-
ortantly, inhaled iloprost appears to induce bronchocon-
triction in some children, which could limit its use but
ould also be prevented in some cases with inhaled steroid
re-treatment. Transition from IV or subcutaneous prosta-
oid therapy to inhaled iloprost may be possible in some
atients under close observation, but long-term follow-up is
ecessary. It can be hoped that the benefits of inhaled
loprost that have been documented in adults with PAH will
e similarly present in children with PAH, but further
tudies are necessary.
eprint requests and correspondence: Dr. Dunbar Ivy, Pediatric
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